… side effects such as uncontrolled jerky movements, called dyskinesia, that negatively impact quality of life. Recent studies show that dyskinesia is associated with another brain … of serotonin neurons is a promising strategy to treat dyskinesia and can be achieved using drugs such as NLX-112. …

… receptor subtype is an attractive strategy to decrease the dyskinesia that arises in Parkinson’s disease (PD) patients … selective drug (NLX-112) completely abolished the dyskinesia-like symptoms observed in pre-clinical … whether NLX-112 maintains is capacity to eliminate dyskinesia and modulate neurotransmitter release. The second …

… their hyperactivation under conditions of levodopa induced dyskinesia (LID).  We propose here an approach to precisely … study in PD patients with LID using this small molecule. … Dyskinesia … Neuropharmacology … Rapid Response Innovation …

… the treatment of PD or for the treatment of L-DOPA induced dyskinesias. Project Description : In part 1, we will … whether this PDE10A is effective in counteracting the dyskinesias seen after repeated treatment with L-DOPA in the … inhibitor, MP-10, and its effects on levodopa-induced dyskinesias in the 6-OHDA pre-clinical model of Parkinson’s …

… disease and side effects of treatment like levodopa-induced dyskinesia (LID) have been poorly studied. We have recently … treatment and determining if it prevents levodopa-induced dyskinesia. We employed a novel approach to kill striatal … The depletion of ChIs markedly attenuated levodopa-induced dyskinesia without compromising the therapeutic efficacy of …

… Prodrug of Acamprosate for Treatment of L-DOPA-Induced Dyskinesias Promising Outcomes of Original Grant : The goal … if a prodrug of acamprosate could inhibit levodopa-induced dyskinesias (LIDs) in a pre-clinical model. During the … PK characteristics and bioavailability of this compound. … Dyskinesia … California … United States … Academia/Nonprofit …